Blood Type O Lowers Myeloma Risk, But Outcomes Typically Worse
People with blood type O are significantly less likely to develop multiple myeloma, but those who do are…
Steve Bryson, PhD, science writer — 
Articles by Steve Bryson
China Approves Xgeva to Prevent Bone Events Due to Multiple Myeloma, Other Cancers
Xgeva (denosumab) has been approved by the China National Medical Products Administration (NMPA) to prevent…
Radiation Therapy Safe for Myeloma Patients Before CAR T-cell Infusion, Study Finds
Administering radiation therapy to people with relapsed or refractory (resistant) multiple myeloma waiting for CAR T-cells to…
Melflufen Open to Select Adults With Advanced Multiple Myeloma in US
Oncopeptides has formally opened sEAPort, its open-label expanded access program allowing adults with…
CHMP Favors Darzalex Faspro in Treating Patients in EU
Janssen‘s new under-the-skin formulation of daratumumab, called Darzalex Faspro, has been recommended for approval…
Gains in 5-Year Survival with Stem Cell Transplant Evident Since Late ’90s
The long-term survival of people with multiple myeloma following autologous stem cell transplant has steadily improved since 1997…
New CAR T-cell Therapy Shows Early Promise Against Multiple Myeloma in Lab Study
A new CAR T-cell therapy  for people with multiple myeloma has been successfully created and tested in…
Pivotal DREAMM-2 Trial Supports Belantamab Mafodotin’s Use for Heavily-treated Multiple Myeloma
Treatment with belantamab mafodotin, GlaxoSmithKline’s investigational antibody-drug conjugate, resulted in clinically meaningful responses in about one-third of hard-to-treat multiple…
Top 10 Multiple Myeloma Stories of 2019
Myeloma Research News brought you daily coverage of important findings, treatment developments, clinical trials, and other events related to multiple myeloma…